The investigation for the critical cause of ERalpha-positive breast cancer and the establishment of its chemoprevention using chemical biology
| Project/Area Number |
26670337
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hygiene and public health
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
Watanabe Motoki 京都府立医科大学, 医学(系)研究科(研究院), 助教 (40723581)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | ANT2 / cyclin D1 / breast cancer / sesaminol / perillyl alcohol / troglitazone / chemical biology / 分子標的癌予防 / ケミカルバイオロジー / ERα陽性乳癌 |
|---|
| Outline of Final Research Achievements |
Breast cancer incidence has been increasing in Japan, which gives us urgent issues of the investigation for the critical cause of breast cancer and the establishment of its chemoprevention. First, we conducted a screen for compounds which inhibited the growth of ERalpha-positive breast cancer cells, and found three hit compounds which reduced the expression level of cyclin D1. Second, we identified the inner mitochondrial membrane protein ANT2 as a common binding protein of these compounds. Finally, we suggested that ANT2 pleiotropically regulated the expression level of cyclin D1 at mRNA and protein levels. Taken together, ANT2 is expected to be a promising target against cyclin D1-overexpressing cancer, including breast cancer.
|
Report
(4 results)
Research Products
(5 results)
